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Abstract
Single long-chain omega-3 fatty acids (e.g. docosahexaenoic acid (DHA) or eicosapentae-
noic acid (EPA)) are known for their neuroprotective properties associated with ischemic
stroke. This pilot study aimed to test the effectiveness of an acute treatment with a long-
chain omega-3 lipid emulsion (Omegaven 10%®, OGV) that contains fish oil (DHA 18 mg/
ml; EPA 21 mg/ml) and α-tocopherol (0.2 mg/ml) in a transient middle cerebral artery occlu-
sion (MCAO) model of ischemic stroke in mice. For this purpose, female CD-1 mice were
anesthetized and subjected to 90 minutes of MCAO. To reflect a clinically relevant situation
for an acute treatment, either after induction of stroke or after reperfusion, a single dose of
OGV was injected intravenously into the tail vein (5 ml/kg b.w.). A neurological severity
score was used to assess motor function and neurological outcome. Stroke-related parame-
ters were determined 24 hours after MCAO. Microdialysis was used to collect samples from
extracellular space of the striatum. Mitochondrial function was determined in isolated mito-
chondria or dissociated brain cells. Inflammation markers were measured in brain homoge-
nate. According to control experiments, neuroprotective effects could be attributed to the
long-chain omega-3 content of the emulsion. Intravenous injection of OGV reduced size and
severity of stroke, restored mitochondrial function, and prevented excitotoxic glutamate
release. Increases of pro-inflammatory markers (COX-2 and IL-6) were attenuated. Neuro-
logical severity scoring and neurochemical data demonstrated that acute OGV treatment
shortly after induction of stroke was most efficient and able to improve short-term neurologi-
cal outcome, reflecting the importance of an acute treatment to improve the outcome. Sum-
marising, acute treatment of stroke with a single intravenous dose of OGV provided strong
neuroprotective effects and was most effective when given immediately after onset of ische-
mia. As OGV is an approved fishoil emulsion for parenteral nutrition in humans, our results
may provide first translational data for a possible early management of ischemic stroke with
administration of OGV to prevent further brain damage.
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Introduction
Ischemic stroke is a major cause of death worldwide and responsible for serious long-time dis-
ability in adults. Thrombolytic treatment provides benefits but only for a small subset of
patients who are suitable for lysis therapy. Neuroprotective treatments are aimed at preserving
neurons and preventing neurodegeneration but have not been proven effective in humans yet.
[1] However, neuroprotection remains a prominent goal for stroke therapy and ischemia-
related damage.[2] Ischemia induces changes in mitochondrial respiration and increased
mitochondria-related oxidative stress.[3] Thus, mitochondria are an important target for neu-
roprotection in ischemic stroke.[4] Experimental studies identified intravenous administration
of the long-chain omega-3 fatty acid docosahexaenoic acid (DHA)—a major component of
fish oil—at least in the next 3 hours following initiation of stroke and 1 hour post-reperfusion
as a potent neuroprotective agent in ischemic stroke.[5] It was concluded that DHA has the
potential for treating focal ischemic stroke in a clinical setting and that acute administration of
DHA enriched lipid emulsions may be an effective intervention in pathogenesis of human
stroke.[6] Early discovery and prevention of long-term sequelae is the primary task in treating
patients with acute ischemic stroke.[7] Therefore, we aimed to test the effectiveness of an intra-
venous injection (5 ml/kg b.w.) of OGV shortly after onset of ischemic stroke or after reperfu-
sion in a transient MCAO mouse model. This situation should reflect two clinically relevant
points in time or situations: First, an early neuroprotective treatment in patients arriving at the
hospital with a suspected ischemic stroke (at stroke). Secondly, a neuroprotective treatment in
patients with diagnosed ischemic stroke after lysis or removal of the thrombus (at reperfusion).
The quantity of OGV used in this study corresponds to a human dose of 0.41 ml/kg.[8] This
dose is in the lower range for human use because OGV is approved for doses up to 2 mL/kg
body weight. OGV is an iso-osmolar lipid emulsion already in clinical use for parenteral nutri-
tion and contains fish oil (DHA 18 mg/ml; EPA 21 mg/ml) and α-tocopherol (0.2 mg/ml). We
decided to use OGV in a transient MCAO mouse model because our findings would be trans-
ferable to a clinical setting, giving a potentially translational outcome. In comparison, earlier
studies used free DHA dissolved in saline which is less suitable for the intended human use.
[9–11] Stroke related parameters were investigated 24 hours after reperfusion and showed
reduced infarct size and infarct severity, improved neurological outcome and behavior,
improved mitochondrial function, enhanced glucose levels, prevention of excitotoxic gluta-
mate release and decreased neuroinflammation.
Materials and Methods
Animals and experimental stroke model
Female CD-1 mice (27-29g) were purchased from Charles River (Sulzbach, Germany) and
kept under standardized conditions: 12 h light/dark cycle, temperature (22˚C), humidity
(70%) and access to food and water ad libitum. All animal procedures were carried out in
order to minimize animal suffering according to German and European law. This study was
registered and approved by local authorities (Regierungspra¨sidium Darmstadt, Antrag F8/21)
and performed by experienced persons with adequate training conforming to the require-
ments of the Federation of European Laboratory Animal Science Associations and the Euro-
pean Communities Council Directive (Directive 2010/63/EU). Omegaven 10%1 (Lot.
16GH0062, containing 18.1 mg/mL DHA and 21.3 mg/mL EPA) was provided by Fresenius
Kabi Deutschland GmbH, Bad Homburg, Germany.
Transient in vivo-ischemia was provoked by occluding the middle cerebral artery (MCAO)
in the left hemisphere of mice. Mice were anesthetized with isoflurane (Forene1, AbbVie
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Deutschland GmbH & Co. KG, Germany) and maintained at 37˚C and received 0.1 mg/kg
buprenorphine as intraperitoneal injection (Temgesic1, Reckitt Benckiser Healthcare Ltd.,
UK) for analgesia. External carotid artery (ECA) and internal carotid artery (ICA) were dis-
sected and a silicon coated suture (Doccol Corp., Redlands, Ca; USA) was introduced and
pushed forward through the ICA until the coated top sealed the source of the middle cerebral
artery (MCA). Proper positioning of the suture was verified by laser Doppler flowmetry.[12]
Mice then recovered in their specified cage. After 90 minutes of occlusion, mice were re-anes-
thetized for suture withdrawal to allow reperfusion. For Sham group, surgery protocol ended
after dissecting the ICA, thus no suture was inserted. In the acute post-operative phase (6
hours after surgery), animals were monitored hourly and every 6–8 hours subsequently. If
signs of pain increased during this time, animals were eligible for additional analgesia of 0.1
mg/kg buprenorphine given intraperitoneally every 6–8 hours. 24 hours after reperfusion, ani-
mals were deeply anesthetized with isoflurane and euthanized by decapitation. In total, 146
mice underwent surgery, of which 28 died during the induction of the stroke and 7 during the
recovery phase. No evidence of adverse effects was identified. The 35 animals who died during
surgery or recovery phase were evenly distributed between the groups. Experiments have been
repeated accordingly.
Treatments
First experiments were carried out to prove potential neuroprotective effects of OGV related
to its content of long-chain omega-3 fatty acids. A control medium-chain lipid emulsion Lipo-
fundin MCT 10%1 (LPF, B Braun, Germany) and d-α-tocopheryl polyethylene glycol 1000
succinate (TPGS1, Sigma-Aldrich, Germany) were tested against saline and OGV in corre-
sponding doses. LPF is also an approved lipid emulsion for parenteral nutrition but lacks long-
chain omega-3 fatty acids whereas TPGS is a water-soluble derivative of α-tocopherol. A com-
parison of the average main ingredients of the two lipid emulsions OGV and LPF is summa-
rized in Table 1.
Throughout the experiments, OGV from a single batch was used to assure constant and
comparable concentrations of its ingredients. Subsequently, mice were randomly divided
and tested in two subprojects: In subproject 1 treatment took place 5 minutes after comple-
tion of the surgical procedures of transient MCAO (a.s., at stroke). In subproject 2 treat-
ment took place after 90 minutes of transient MCAO (a.r., at reperfusion). Each subproject
consisted of three groups: (1) Sham, (2) stroke control and (3) stroke OGV. Control and
verum groups received a single bolus injection of approximately 150 μL (5 ml/kg b.w.)
saline or OGV into the tail vein. According to earlier studies on long-chain omega-3 fatty
acids and to exclude possible aggravating effects of other fatty acids such as n-6 fatty acids
or saturated fatty acids, we chose saline as a control throughout the experiments.[9–11,13–
16]
Table 1. Comparison of average main-ingredients of Omegaven 10% and Lipofundin 10% MCT.
per 100 mL Omegaven 10% Lipofundin 10% MCT
Fishoil 10,00g -
Soybean oil - 5,00
Medium-chain-triglycerides (MCT) - 5,00
Glycerol 2,50g 2,50g
α-Tocopherol 0,02g 0,01g
(3-sn-Phosphatidyl-)choline from egg 1,20g 0,8g
doi:10.1371/journal.pone.0167329.t001
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Neurobehavioral Assessment
Behavioral tests were performed 1 hour before stroke surgery and 24 hours after reperfusion.
Neurological impact was scored using a neurological severity score (NSS) adapted from pub-
lished scores.[17,18] The NSS combines different measures of innate reflex, alertness, physio-
logical behavior and motor ability to score neurological behavior. Neurological performance
was scored on a scale of 0 to 16 (most healthy score = 0, most severe score = 16; refer to S1
Table).
Infarct area and infarct severity
Infarct area was measured 24 hours after reperfusion. Brain slices were stained with a solution
of 1% 2,3,5-triphenyl-tetrazolium chloride (TTC, Sigma-Aldrich, Germany) in phosphate buff-
ered saline (PBS). Striatal brain slices from core region of ischemic stroke (due to MCAO)
were used to determine the infarct areas and infarct severity as measured by differences in
grayscales. Infarct volumes were determined by whole brain slices.
Stroke severity or amount of living tissue was determined by a grayscale analysis of TTC
stained brain slices. The coloring agent allows to differentiate between metabolic active and
inactive tissue in a continuous way, as density and intensity which is measured by grayscale
varies depending on severity of stroke.[19] The colorless compound is transformed to a red
dye by metabolic active tissue whilst metabolic inactive tissue remains white. The difference
between the mean grayscale of impacted and healthy contralateral brain hemisphere was calcu-
lated for each animal. The lower the value, the more healthy tissue in the analyzed area, as a
value of zero implies that there is no difference in the TTC stained color of impacted and con-
tralateral brain hemisphere. Stroke area and grayscale analysis were achieved by Image J soft-
ware (National Institutes of Health, USA. Version 1.46r).[20]
Preparation of dissociated brain cells (DBC) for ex vivo studies
DBC were prepared according to a previously published method using separated hemispheres
of brains.[21] Briefly, brain was washed and homogenized in a buffered medium, chopped and
pressed through a nylon mesh for separation followed by several centrifugation steps. Subse-
quently on receipt of the pellet, DBCs were diluted in Dulbecco’s Modified Eagle Medium
(DMEM) and seeded into 24 well plates or 96 well plates. Cells were cultured at 37˚C under
5% CO2. DBCs were used for analysis of MMP and ATP levels 24 hours after reperfusion.
Mitochondrial function
For Mitochondrial isolation, separated hemispheres of brains were homogenized as previously
decribed.[22] Briefly, the sample passes through different centrifugal steps after homogeniza-
tion to isolate mitochondria which were finally injected into a respirometer (Oxygraph-2k,
Oroboros, Innsbruck, Austria).
Mitochondrial respiratory function was assessed by measuring consumption of oxygen in an
Oxygraph-2k respirometer. Titrations of substrates and inhibitors induced different respira-
tory states. Mitochondrial respiration was normalized to protein content and citrate synthase
(CS) activity., respectively. CS activity and protein content were assessed in isolated
mitochondria.
Mitochondrial Membrane Potential (MMP) measurement was assessed in DBCs using the
fluorescence colorant rhodamine-123 (R123) for analysis. DBCs were incubated for 15 min
(37˚C, 5% CO2) with 0.4 μM R123. DBC were centrifuged (3000 rpm, 5 min) and washed with
HBSS buffer (supplemented with Mg2+, Ca2+, and HEPES; pH 7.4; 37˚C). After adding fresh
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HBSS to the DBCs, MMP was obtained by measuring the fluorescence of the colorant at an
excitation wavelength of 490 nm and at an emission wavelength of 535 nm on a Victor X3
2030 multilabel counter (Perkin Elmer, Rodgau-Ju¨gesheim, Germany). The fluorescence was
recorded in four sequential runs and normalized to corresponding protein concentrations.
ATP levels were determined in DBCs using a ViaLight1 Plus bioluminescence kit (Lonza,
Walkersville, USA). Briefly, DBCs were incubated with lysis reagent followed by incubation
with monitoring reagent for additional 5 min. Bioluminescence (linearly associated to ATP
concentration) was obtained by a luminescence reader (Victor X3 2030 multilabel counter,
Perkin Elmer, Rodgau-Ju¨gesheim, Germany). Concentrations were recorded in two sequential
runs and normalized to corresponding protein concentrations.
Microdialysis
Microdialysis was performed as previously described.[23] Briefly, self-made dialysis probe was
implanted into mouse striatum one day prior to MCAO. Anesthesia was induced by 2.4% iso-
flurane with synthetic air and fixed in a stereotaxic framework. The probe (exchange length
2.5mm) was implanted AP +0.5mm; L +2.2mm; DV -3.8mm from bregma and fixed at this
position with dental cement (Ivoclar Vivadent AG, Schaan, Liechtenstein). Mice recovered
from surgery in their specified cages for 24 hours. Microdialysis was initiated 30min before
MCAO and continued until 30min after reperfusion. Fractions were collected separately
(before, during and after occlusion). Perfusion liquid was artificial cerebrospinal fluid (aCSF:
147 mmol/LNaCl; 4 mmol/LKCl; 1.2 mmol/L CaCl2 and 1.2 mmol/L MgCl2), the perfusion
rate was 2 μL/min. After completion of the microdialysis, animals were sacrificed by decapita-
tion. Metabolites were determined using a CMA-600 microanalyzer (CMA Microdialysis,
Stockholm, Sweden).
Protein quantification and Western blot analysis
Protein levels were determined by using Pierce BCA Protein Assay Kit (Thermo Scientific,
USA). Brain homogenate of separated hemispheres was used for Western blot experiments.
Samples were incubated with primary antibodies [(Cox-2 (sc-1745), Santa Cruz Biotechnology,
USA; IL-6 (PP012P2), IL10 (PP007P2), Acris Antibodies, USA] and corresponding secondary
antibodies (#401515, #401353 and #401253, Calbiochem, Germany) conjugated to horseradish
peroxidase and visualized by ECLplusTM Reagent (Amersham Biosciences, USA). Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) detected with antibody (MAB374, Chemicon,
Germany) and Tubulin detected with antibody (ab6160, Abcam, GB) served as loading control.
Band detection and evaluation was achieved with BioRad’s Quantity One software.
Statistics
All data are presented as means ± SEM. Statistical analysis was performed by applying t-test
and Mann-Whitney test for groups of two and One-Way ANOVA with Tukey post test for
groups of more than three (Prism 5.03, GraphPad Software, USA). A P value of< 0.05 was
considered statistically significant. If not declared differently, significances always refer to con-
trol values.
Results
Neuroprotection by intravenous infusion of OGV at reperfusion
Transient MCAO for 90 minutes disrupted blood flow and caused ischemia in striatal and cor-
tical areas of the brain as detected by laser Doppler (data not shown) and striatal glucose levels.
Long-Chain Omega-3 Lipid Emulsion as Acute Treatment of Ischemic Stroke
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LPF and TPGS, control items both lacking long-chain omega-3 fatty acids (refer to Table 1 for
a list of main ingredients) neither affect stroke area (Fig 1A and 1C) nor stroke severity as mea-
sured by grayscale analysis (Fig 1B and 1C). OGV injection at reperfusion (a.r.) reduced the
infarcted area by 21% and severity of stroke by 50% (Fig 1A, 1B and 1C).
Compared to the stroke control group, OGV a.r. increased the mitochondrial membrane
potential by 20% (MMP; Fig 2A), and ATP levels by 63% (Fig 2B) which were significantly
reduced in dissociated brain cells 24 hours after reperfusion. Protective effects of OGV on
cerebral mitochondrial dysfunction were further investigated in isolated mitochondria.
Stroke significantly impaired the activity of OXPHOS and complex IV (cytochrome c oxi-
dase) of the mitochondrial respiration chain (Fig 2C) and reduced the respiratory control ratio
(RCR) and citrate synthase activity (Fig 2D). OGV improved the RCR by 31% (Fig 2D),
Fig 1. Effects of OGV and control emulsions when applied at reperfusion. Saline, Lipofundin® (LPF) and d-α-tocopheryl polyethylene glycol 1000
succinate (TPGS) in doses equal to OGV when injected at reperfusion (a.r.). (A) Infarct areas and (B) differences in grayscale for LPF, TPGS, and Omegaven
10% (OGV) vs. Saline; n = 6. Mean ± SEM, p*<0.05; p**<0.01; p***<0.001; One-Way ANOVA with Tukey post-test. (C) Representative striatal brain slices
for determination of differences in grayscale for each group. Density of grayscale in a representative area from core of infarction (solid circle) was subtracted
from corresponding grayscale of contralateral control area (dashed circle).
doi:10.1371/journal.pone.0167329.g001
Long-Chain Omega-3 Lipid Emulsion as Acute Treatment of Ischemic Stroke
PLOS ONE | DOI:10.1371/journal.pone.0167329 November 30, 2016 6 / 18
Long-Chain Omega-3 Lipid Emulsion as Acute Treatment of Ischemic Stroke
PLOS ONE | DOI:10.1371/journal.pone.0167329 November 30, 2016 7 / 18
indicating enhanced coupling of the respiratory system.[22,24] OGV also increased citrate
synthase activity by 71% after stroke (Fig 2D), indicating enhanced mitochondrial mass.[25]
Although mitochondrial function as well as stroke area and severity of stroke were
improved, OGV treatment at reperfusion resulted only in marginally improved neurological
severity scores as early as 24 hours after reperfusion (data not shown).
Superior effects of an acute OGV administration
Severe behavioral limitations (score 10 or 11) were manifest in all animals tested 24 h after 90
minutes of MCAO (Fig 3A). Significant improvement was observed when OGV was injected
immediately after onset of MCAO (a.s.) (Fig 3A), resulting in a significant improved motor
function.
MCAO led to steady necrotic lesions including both cortical and subcortical areas of the
impacted, left hemisphere (Fig 3B). OGV injection a.s. reduced infarct volume by 56% as well
as severity of stroke by 60% (Fig 3B and 3C) and restored mitochondrial function to basal val-
ues (Fig 4A and 4B).
Glucose and glutamate levels were determined before (PRE), during (Stroke) and after
stroke (POST) in extracellular microdialysates collected in the striatum of the ischemic hemi-
sphere (Fig 4C and 4D). Glucose levels dropped by 86% during stroke and increased after
reperfusion (Fig 4C). Elevated glutamate levels by 740% of basal values were observed during
MCAO (Fig 4D). OGV suppressed the release of glutamate during stroke (Fig 4D) and
enhanced glucose levels in the impacted area (Fig 4C). Although, the OGV-induced rise in glu-
cose levels was statistically not significant, the data indicate an improved blood supply into the
affected tissue.
MCAO significantly increased pro-inflammatory protein levels of cyclooxygenase 2 (COX-
2, Fig 5A) by 540% and interleukin-6 (IL-6 Fig 5B) by 220% as well as the anti-inflammatory
marker Interleukin-10 (IL-10, Fig 5C) by 160%.
Compared to stroke, OGV a.s. significantly reduced the pro-inflammatory marker IL-6 by
49% (Fig 5B), but had no influence on IL-10 levels. All protein levels were measured 24h post-
stroke.
Discussion
The demand for long-chain omega-3 fatty acids escalates dramatically after ischemic stroke to
limit the cellular damage by restoring destroyed neuronal membranes. During ischemia, poly-
unsaturated species from phospholipids (especially arachidonic acid and DHA) undergo sig-
nificant hydrolysis which was not inversed through reperfusion.[26] We confirmed recent
data demonstrating neuroprotective effects of DHA in experimental stroke models when
applied at reperfusion.[5,11] Moreover, we report the novel finding that OGV injections
shortly after onset of stroke provided superior neuroprotective actions (compared to treatment
at reperfusion) on stroke volume, tissue health (as measured by grayscale analysis), mitochon-
drial function and development of inflammation in a murine MCAO model, emphasizing the
Fig 2. Marker of mitochondrial function after treatment at reperfusion. Sham-operated mice. (Control)
versus stroke control group that received saline (Stroke) and stroke treatment group that received OGV at
reperfusion (a.r.). (A) Mitochondrial membrane potential (MMP)- and (B) Adenosine triphosphate (ATP)-levels
as measured 24 hours after reperfusion in dissociated brain cells, n = 8; (C) Respiration [pmol oxygen/(s*mg
protein)] of different complexes of the respiratory chain were determined in isolated mitochondria, n = 6; (D)
Respiratory control ratio (RCR) that indicates the coupling of mitochondrial respiration chain and citrate
synthase activity that represents a quantitative marker for mitochondrial mass, n = 6. Mean ± SEM, p*<0.05;
p**<0.01; p***<0.001; One-Way ANOVA with Tukey post-test.
doi:10.1371/journal.pone.0167329.g002
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Fig 3. Effects of OGV when given at stroke (a.s.). (A) Neurobehavioral assessment (refer to S1 Table) for sham-operated mice (Control) versus control
group that received saline (Stroke) and treatment group that received OGV at stroke (a.s.), (B) Representative brain slices for determination of infarct volume
and differences in grayscale. (C) Effect on infarct volume and grayscale levels, n = 8. Mean ± SEM, p*<0.05; p**<0.01; p***<0.001; (A) One-Way ANOVA
with Tukey post-test, (C) t-test.
doi:10.1371/journal.pone.0167329.g003
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importance of an earliest intervention to improve the outcome. OGV is an approved fish oil
emulsion for parenteral nutrition containing long-chain omega-3 fatty acids (DHA 18 mg/ml;
EPA 21 mg/,ml) and α-tocopherol (0.2 mg/ml). Thus, findings might be translated into a clini-
cal setting. The dosing rationale for this study was based on recommendations of the GV-SO-
LAS (Gesellschaft fu¨r Versuchstierkunde–Society for Laboratory Animal Science) regarding
the maximum feasible volume for intravenous substance application in the mouse, which is
Fig 4. Marker of mitochondrial function after treatment at stroke. Sham mice (Control) versus stroke control group that received saline (Stroke) and
stroke treatment group that received OGV at stroke (a.s.). (A) Mitochondrial membrane potential (MMP)- and (B) Adenosine triphosphate (ATP)-levels as
measured in dissociated brain cells 24 hours after reperfusion. Energy metabolite levels in striatal core region of stroke for (C) glucose and (D) glutamate as
determined by microdialysis 30 minutes before (PRE), 90 minutes during (Stroke) and 30 minutes after (POST) stroke surgery, n = 8. Mean ± SEM, p*<0.05;
p**<0.01;p***<0.001; One-Way ANOVA with Tukey post-test.
doi:10.1371/journal.pone.0167329.g004
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5 ml/kg and is equal to our bolus injection of 150 μL in a mouse of approximately 30g weight.
[27] This dose is 5 times below the accepted range of OGV in human. Belayev et al. reported
toxic effects of 70 mg/kg DHA in rats. Doses of 3.5, 7, 14 and 35 mg/kg DHA showed equal
beneficial effects.[11] Taking into account the conversion factor for doses from rats to mice,
3.5, 7, 14, 35 and 70 mg/kg in rats as reported by Belayev et al. correspond to doses of 7, 14, 28,
70 and 140 mg/kg in mice.[28] The bolus injection used in this pilot study contained 90 mg/kg
DHA, which is below the dose that showed detrimental effects and within the beneficial dose
that was reported by Belayev et al., thus reflecting a maximum non-toxic dose. This study was
designed as a pilot study and should test a potentially translational treatment with long-chain
omega-3 fatty acid emulsion approved for parenteral nutrition in humans. We identified two
time points when treatment could take place in the best case: First, after induction of stroke
but before diagnosis, and second, after diagnosis of stroke and lysis/removal of the thrombus.
These points reflect the two earliest time points when treatment with OGV would be feasible
and could potentially exert maximum effects. As patients with suspected or diagnosed ische-
mic stroke would receive a central venous access, we chose an intravenous injection as acute
way of treatment. As stated above, we carefully chose one dose that should represent a maxi-
mum non-toxic dose based on earlier findings in the literature.[11] Beneficial effects of OGV
can largely be assigned to their content of long-chain omega-3 fatty acids since experiments
using comparable emulsions containing soy oil and medium-chain triglycerides (100 mg/ml)
and α-tocopherol (0.2 mg/ml) (LPF or TPGS) in equivalent concentration showed no effects
on stroke outcome. Beside DHA, OGV also contains the long-chain omega-3 fatty acid eicosa-
pentaenoic acid (EPA) which also provides beneficial effects.[29] EPA also exerts anti-inflam-
matory as well as mild vasodilatory effects.[30,31] Exclusive treatment with EPA was shown to
be ineffective in a model of hypoxic-ischemic brain injury, thus its neuroprotective potency
seems to be lower than that of DHA which mediated strong neuroprotection in the same
model.[6] EPA showed additional effects like vasodilatation and improved membrane fluidity
that, in combination with DHA, may potentiate neuroprotective actions.[31] The biological
precursor of long-chain omega-3 fatty acids DHA and EPA is the shorter-chain fatty acid
Fig 5. Western Blot analysis of brain homogenates. Sham-operated mice (Control) versus control group that received saline (Stroke) and treatment group
that received OGV at stroke (a.s.). (A) COX-2-, (B) IL-6-, and (C) IL-10 protein levels, n = 8. Mean ± SEM, p*<0.05; p**<0.01; p***<0.001; One-Way ANOVA
with Tukey post-test.
doi:10.1371/journal.pone.0167329.g005
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alpha-linolenic acid (ALA). In the body, ALA is converted to DHA and EPA, but this conver-
sion is ineffective. For example, conversion from ALA to DHA is only about 0–4%.[32] A
recent study showed that acute intravenous injection of ALA was insufficient in improving
motor recovery after ischemic stroke in mice, whilst dietary long-term supplementation with
ALA was able to exert significant protective effects, emphasizing the importance and possibil-
ity of nutritional intervention in order to improve outcome in the critically post-stroke recov-
ery phase.[33] Other studies claim that neuroprotective effects are widely attributed to
conversion of ALA to DHA and that ALA seems not to be useful for an acute intervention of
ischemic stroke.[34] Respective levels of ALA and EPA in the brain are 200–500 fold lower
than of DHA, which might be attributed to a rapid metabolism via beta-oxidation and subse-
quently underline the brain’s need for DHA.[35] Otherwise, Bourourou et al. revealed that
protective effects of ALA treatment are linked to an intrinsic effect rather than bioconversation
of ALA to DHA as indicated by unchanged DHA levels of the brain after subchronic ALA
injections.[33] As OGV also contains certain amounts of ALA, this might also contribute to
the observed protective effects in addition to those mediated by e.g. DHA or EPA.[36] Addi-
tional data for ALA supplementation and its protective effects are also given by Blondeau et al.
who summarizes that potential benefits of ALA are supported by animal studies as well as epi-
demiologic studies. He also supports the idea of an intravenous therapy targeting neurological
conditions and speculates that this may offer significant benefits for patients suffering ischemic
conditions.[37] The proposed intervention with OGV goes well with the supposed approach
communicated by Blondeau et al. and supports this idea with first data.
In line with earlier reports, microdialysis showed significantly increased glutamate levels in
the striatum of control mice which returned to basal levels at reperfusion.[38] Excessive gluta-
mate release during ischemia leads to excitotoxicity that triggers apoptosis and finally neurode-
generation.[39,40] The excessive glutamate release peaks within minutes after ischemia and
then slowly decreases within hours, emphasizing the importance of an early treatment if the
glutamate mediated excitotoxicity should be targeted effectively to prevent further neuronal
death.[12,23,41] We recently showed that the inhibition of the excessive release of glutamate
triggered by ischemia results in a reduction of infarct area and enhances motor function.[20]
Similarly, OGV treatment shortly after induction of MCAO abolished the release of extracellu-
lar glutamate levels and reduced the infarct area which might help to explain why only an
acute treatment improved neurological outcome. Presumably, due to the fact that also treat-
ment at reperfusion preserved significant amounts of viable brain tissue, long-term rehabilita-
tion is expected to be better. Supplementation with fish oil was recently shown to be related to
reduced cellular damage and enhanced cellular proliferation 6 weeks after ischemic stroke in
the rat.[42] OGV numerically enhanced glucose levels. OGV enhances erythrocyte membrane
fluidity and thus potently modulates endothelial cell integrity and exert vasodilatory effects
which might explain an improved blood supply into the affected tissue, thus leading to slightly
improved glucose levels obtained during microdialysis at stroke.[30,31,43] As a consequence,
this mechanism might evoke concern about influences on bleeding times. Wachira et al. inves-
tigated the influence of (highly concentrated) long-chain omega-3 fatty acids on hemostasis
and concluded that bleeding times did not exceed normal limits nor did produce clinically sig-
nificant bleeding episodes and are rendered safe in monotherapy as well as combination ther-
apy settings, although DHA and EPA exert a mild inhibition of platelet function that was often
under detection limits. No support for discontinuing long-chain omega-3 fatty acid supple-
mentation before invasive procedures was found. In contrast, their use improved clinical out-
comes in several settings or reduced the risk of bleeding.[30] This finding is supported by a
meta-analysis of clinical studies regarding relation of intake of long-chain omega-3 fatty acids
and stroke by Larsson et al. who showed that no higher risks nor occurrences of hemorrhagic
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stroke could be stated, but a statistically significant reduction in stroke risk in relation to long-
chain omega-3 fatty acid intake could be found for ischemic stroke that was only significant
for ischemic but not hemorrhagic stroke. Larsson et al. attributed this statistical difference to
the higher patient counts for ischemic stroke, resulting in higher statistical power.[44] A recent
study focused on the concern of hemorrhagic transformation and tested whether DHA
increases or decreases the risk of hemorrhagic transformation as a feared complication of cere-
bral ischemic infarction.[45] The results of this study showed that DHA attenuated hemor-
rhagic transformation and preserved integrity of the blood-brain-barrier whilst reducing
inflammation.
Mitochondrial dysfunction is a major consequence of stroke that impacts brain tissue and
causes elevated levels of reactive oxygen species (ROS) in the affected tissue.[46] Ischemia pro-
vokes negative alterations in mitochondrial respiration in animal models.[3] In mitochondria,
efficacy of cellular respiration was significantly decreased. In contrast, the degree of lipid per-
oxidation mediated through increased formation of free radicals was significantly increased
during ischemia and reperfusion.[20,26,47] In line with recent findings we report on impaired
mitochondrial function after MCAO.[41] Intravenous treatment with OGV compensated for
stroke-related decrease of mitochondrial respiration and significantly enhanced OXPHOS and
cytochrome C oxidase activity. The OXPHOS system is the final biochemical pathway for the
production of ATP. Thus, improved respiration led to an enhanced MMP that represents the
propulsive power for ATP formation through F0/F1-ATPase (complex V) activity.[48]
Accordingly, OGV significantly improved MMP and ATP levels as measured 24 hours after
reperfusion.
Inflammation represents a severe and detrimental consequence of stroke that is character-
ized by an accumulation of inflammatory mediators.[49] Pro-inflammatory mediators such as
COX-2 impair mitochondrial activity by inducing accumulation of distinct amounts of ROS
through impairing OXPHOS activity.[50] Pro-inflammatory IL-6 is known to be elevated in
the acute phase of stroke and high levels of IL-6 are associated with increased stroke volume
and less favorable prognosis.[51] Its opponent IL-10 exerts anti-inflammatory effects, provides
neuroprotection in ischemic stroke and reduced infarct volume at raised levels.[52] Levels of
IL-6 (as part of the pro-inflammatory answer) and IL-10 (as part of the physiological repair
mechanism to control the inflammatory answer) were significantly increased after transient
MCAO which may involve inhibition of nuclear factor κB activation and an ERK mediated
pro-survival cascade.[53] Several studies reported that treatment with anti-inflammatory
drugs reduced infarct size and brain edema.[54] Long-chain omega-3 fatty acids are consid-
ered to be suppressors of neuroinflammation with several mechanisms of action.[35] Long-
chain omega-3 fatty acids are actively biosynthesized to specialized pro-resolving mediators
(SPM), a family of neuroprotective mediators that are involved in the resolution of inflamma-
tion.[55] This family is comprised of lipoxins, resolvins, protectins and maresins. Classic lipid
mediators are formed from arachidonic acid and can exert pro-inflammatory (leukotrienes) or
anti-inflammatory (lipoxins) actions. EPA can be biosynthesized to a class of resolvins (e-series
resolvins) and DHA to several classes of resolvins (d-series resolvins), protectins and maresins
which are all actively involved in the resolution of inflammation.[30,55–57] Resolution of
inflammation by SPMs involves several mechanisms like neutrophil recruitment, stimulation
of clearance mediated by macrophages, counterregulation of pro-inflammatory mediators
such as COX-2 or IL-6 and tissue remodeling.[56] Neuroprotectin D1 (NPD-1) represents one
of the first and most prominent neuroprotective metabolites of DHA which was identified by
Bazan et al. earlier.[58,59] NPD-1 is a protectin that attenuates leukocyte infiltration, inhibits
pro-inflammatory signaling and reduces infarct size in animal models of ischemic stroke via
inhibition of Nf-κB pathway activation, increased expression of anti-apoptotic proteins like
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Bcl-2 and decreased expression of pro-apoptotic protein such as Bax.[5,60,61] Since DHA can
be converted to several different classes of SPMs which each of them individually exert potent
neuroprotective and anti-inflammatory effects, it is one of the most important members of
long-chain omega-3 fatty acids.[56] OGV treatment significantly decreased protein levels of
IL-6 confirming its anti-inflammatory properties.[62] Our experiments indicate that transient
MCAO induced inflammatory and anti-inflammatory proteins and that OGV diminished the
pro-inflammatory response only. A crucial point in time for inflammation is the moment of
reperfusion. Paradoxically, reperfusion after removal of the thrombus does not improve the
overall situation of the brain. As mitochondria experience dysfunction due to previously
restricted supply with blood, glucose and oxygen, complexes of the respiratory chain do not
work as intended: Components of the oxidative phosphorylation (OxPhos) are phosphorylized
under physiological conditions and stabilize mitochondrial membrane potential in a range
between 80–140 mV what is advantageous for the production of energy.[63] Following ische-
mia, several enzymes get activated that mediates dephosphorylation of components of the
OxPhos which triggers a hyperactive state with a membrane potential above 150 mV. This
hyperactivation does not result in consequences during ischemia due to the lack of oxygen.
But after reperfusion, hyperactivated OxPhos components are supplied with oxygen, resulting
in exponentially increased production of reactive oxygen species triggering further inflamma-
tion and apoptosis.[63] This detrimental phenomenon is called reperfusion-injury, emphasiz-
ing the need of an early intervention.[64]
Our data identified intravenous injection of OGV shortly after onset of transient MCAO as
possible early medical management which could play a crucial role in inhibiting further brain
damage mediated by ischemic stroke.[65] As literature did not reveal any concerns about pos-
sible influences of long-chain omega-3 fatty acids on bleeding times, treatment could also be
started precautionary when stroke diagnosis is not fully performed yet. [30,44] Earliest neuro-
protective treatment of ischemic stroke even before removal of thrombus showed best effects
in our pilot study and was able to improve functional short-term outcome. This may be related
to the reperfusion-injury that could be targeted by anti-inflammatory and anti-apoptotic long-
chain omega-3 fatty acids and their neuroprotective metabolites when given during onset of
ischemia. Although this pilot study showed short term effects only, it proved effectiveness of
the proposed treatment. Further studies are needed to investigate the long-term effects of the
proposed treatment and possibly further dosing regimens. Nevertheless, our results provide a
translational approach that might contribute to a new and acute treatment of ischemic stroke
in the clinics.
Conclusion
In summary, treatment provided distinct neuroprotective properties in acute focal cerebral
ischemia in mice by attenuating mitochondrial dysfunction as well as neuroinflammation and
excitotoxicity. Neuroprotective effects were associated with the long-chain omega-3 fatty acid
content of the lipid emulsion. Thus, intravenous administration of OGV might be an early and
safe option for interventions even before diagnosis of ischemic stroke has been established.
The results of this study might provide first translational data for an early clinical management
of ischemic stroke with OGV which is pivotal to prevent further brain damage.
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